Abivax
ABVXPhase 3Abivax is a biopharmaceutical company focused on developing first-in-class therapies for inflammatory diseases and viral infections. Their lead candidate obefazimod represents a novel mechanism targeting RNA splicing to modulate immune responses. The company is publicly traded and has advanced multiple programs into clinical development, with a primary focus on inflammatory bowel disease and other immune-mediated disorders.
ABVX · Stock Price
Historical price data
AI Company Overview
Abivax is a biopharmaceutical company focused on developing first-in-class therapies for inflammatory diseases and viral infections. Their lead candidate obefazimod represents a novel mechanism targeting RNA splicing to modulate immune responses. The company is publicly traded and has advanced multiple programs into clinical development, with a primary focus on inflammatory bowel disease and other immune-mediated disorders.
Technology Platform
Small molecule modulators targeting RNA splicing mechanisms and viral replication processes to treat inflammatory diseases and viral infections.
Pipeline Snapshot
2222 drugs in pipeline, 6 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| ABX464 + Placebo | Ulcerative Colitis | Phase 3 |
| ABX464 + Placebo | Ulcerative Colitis | Phase 3 |
| ABX464 + Placebo | Ulcerative Colitis | Phase 3 |
| ABX464 + Placebo | COVID-19 | Phase 2/3 |
| ABX203 therapeutic Hepatitis B vaccine treatment arm | Chronic Hepatitis B | Phase 2/3 |
Funding History
3Total raised: $85M
Opportunities
Risk Factors
Competitive Landscape
Competes with established players like AbbVie, Janssen, and Takeda in IBD, but differentiated by novel oral mechanism. In HIV cure space, competing in largely unproven therapeutic area with high regulatory uncertainty.
Company Info
Trading
Contact
Therapeutic Areas
Sectors
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile